Elranatamab
This bispecific antibody brings immune cells into direct contact with myeloma cancer cells to help destroy them. It is used for patients with relapsed or treatment-resistant multiple myeloma.
치료 영역
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
This bispecific antibody brings immune cells into direct contact with myeloma cancer cells to help destroy them. It is used for patients with relapsed or treatment-resistant multiple myeloma.
Yes, Elranatamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297809. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="elranatamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/elranatamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/elranatamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/elranatamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="elranatamab"></drugfyi-drug>